Signal sequence that induces protein secretion in intestinal microbiome
US-2024190925-A1 · Jun 13, 2024 · US
US9499592B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9499592-B2 |
| Application number | US-201213353662-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jan 19, 2012 |
| Priority date | Jan 26, 2011 |
| Publication date | Nov 22, 2016 |
| Grant date | Nov 22, 2016 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
Provided herein are compositions, kits and methods useful in the construction of designer transcription activator-like effector (dTALE) polypeptides.
Opening claim text (preview).
We claim: 1. A nucleic acid molecule encoding a designer transcription activator-like effector (dTALE) polypeptide fragment, the nucleic acid molecule comprising a sequence encoding a nucleic acid binding domain of the dTALE polypeptide fragment and one or more mammalian effector domains, wherein the sequence encoding the nucleic acid binding domain comprises a sequence encoding two or more monomer units arranged in a predetermined 5′ to 3′ non-endogenous TALE order, wherein each said monomer unit comprises a variable diresidue that is capable of specifically binding a target nucleotide, wherein the nucleic acid binding domain encoded by the nucleic acid molecule is capable of specifically binding a predetermined target nucleic acid sequence, wherein each of the one or more mammalian effector domains encoded by the nucleic acid molecule is capable of mediating an effector function, and wherein the nucleic acid molecule further comprises an expression vector comprising the sequence of an expression vector of SEQ ID NOs: 192-195. 2. The nucleic acid molecule of claim 1 , wherein the two or more monomer units of the sequence comprise: a) the monomer units of a TALE polypeptide of SEQ ID NOs: 4-167; the monomer units encoded by the nucleic acid sequences of SEQ ID NOs: 168-171; or the monomer units of SEQ ID NOs: 172-191; or b) an amino acid sequence that is at least 70% identical to: the monomer units of a TALE polypeptide of SEQ ID NOs: 4-167; the monomer units encoded by the nucleic acid sequences of SEQ ID NOs: 168-171; or the monomer units of SEQ ID NOs: 172-191. 3. The nucleic acid molecule of claim 1 , wherein the predetermined target nucleic acid sequence to which the nucleic acid binding domain specifically binds comprises a bacterial, protozoan, fungal, animal, or viral nucleic acid sequence. 4. The nucleic acid molecule of claim 1 , wherein the nucleic acid molecule further comprises at least one nucleic acid sequence: a) of an expression vector; b) of a nuclear localization signal; c) encoding an N-terminal domain that is at least 70% identical to an amino acid sequence of an N-terminal domain from a transcription activator-like effector (TALE) polypeptide from a bacterium of the genus Xanthomonas , or a fragment thereof, and wherein the at least one nucleic acid sequence encoding the N-terminal domain is 5′ of the sequence encoding the nucleic acid binding domain of the dTALE polypeptide; d) encoding a C-terminal domain that is at least 70% identical to an amino acid sequence of a C-terminal domain from a transcription activator-like effector (TALE) polypeptide from a bacterium of the genus Xanthomonas , or a fragment thereof, and wherein the at least one nucleic acid sequence encoding the C-terminal domain is 3′ of the sequence encoding the nucleic acid binding domain of the dTALE polypeptide; or e) any combination thereof. 5. The nucleic acid molecule of claim 4 , wherein the nucleic acid molecule comprises: a sequence encoding an N-terminal domain that is at least 70% identical to the amino acid sequence of an N-terminal domain sequence from a transcription activator-like effector (TALE) polypeptide from a bacterium of the genus Xanthomonas , or a fragment thereof, and wherein the sequence encoding the N-terminal domain is 5′ of the sequence encoding the nucleic acid binding domain of the dTALE polypeptide; a sequence encoding a C-terminal domain that is at least 70% identical to the amino acid sequence of a C-terminal domain from a transcription activator-like effector (TALE) polypeptide from a bacterium of the genus Xanthomonas , or a fragment thereof, and wherein the sequence encoding the C-terminal domain is 3′ of the sequence encoding the nucleic acid binding domain of the dTALE polypeptide; or a combination thereof, and the TALE polypeptide from a bacterium of the genus Xanthomonas comprises a sequence of SEQ ID NOs: 4-167. 6. The nucleic acid molecule of claim 1 , wherein the variable diresidue of at least one of the monomer units is an engineered variable diresidue capable of specifically binding a predetermined target nucleotide. 7. The nucleic acid molecule of claim 1 , wherein the sequence encoding two or more monomer units is an engineered sequence capable of minimizing sequence repetitiveness among the monomer units encoded by the nucleic acid molecule. 8. The nucleic acid molecule of claim 1 , wherein a monomer unit encoded at the 5′ end of the nucleic acid molecule specifically binds to a thymine nucleotide. 9. The nucleic acid molecule of claim 6 , wherein the variable diresidue of at least one of the monomer units encoded by the nucleic acid molecule is an engineered variable diresidue capable of specifically binding the predetermined target nucleotide by encoding NG for specifically binding thymine, HD for specifically binding cytosine, NI for specifically binding adenine, or NN for specifically binding guanine. 10. The nucleic acid molecule of claim 1 , wherein the sequence encoding the two or more monomer units is contiguous and does not comprise insertion or deletion of nucleic acid sequences. 11. The nucleic acid molecule of claim 4 , wherein the expression vector, the one or more mammalian effector domains, the nuclear localization signal, or a combination thereof has activity in a host cell that is not a plant cell. 12. The nucleic acid molecule of claim 1 , wherein the effector function comprises a nuclease function, recombinase function, epigenetic modifying function, transposase function, integrase function, resolvase function, invertase function, protease function, DNA methyltransferase function, DNA demethylase function, histone acetylase function, histone deacetylase function, transcriptional repressor function, transcriptional activator function, DNA binding protein function, transcription factor recruiting protein function, nuclearlocalization signal function, cellular uptake signal activity function, or any combination thereof.
from bacteria · CPC title
stimulating, promoting or activating activity · CPC title
containing a nuclear localisation signal · CPC title
Fusion polypeptide · CPC title
containing spectroscopic/fluorescent detection, e.g. green fluorescent protein [GFP] · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.